• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Does Illumina Have the Genes for Lasting Growth?

This week's introduction of the NovaSeq Series of genomic sequencers caused the stock to jump.
By CHRIS LAUDANI Jan 12, 2017 | 09:00 AM EST
Stocks quotes in this article: ILMN

On Tuesday, shares of Illumina (ILMN) shot up 15% after the genomic sequencing powerhouse confirmed the introduction of a new line of products. In the last 30 days the shares have increased 32%. Still, Illumina investors have had a rough ride after the company cut guidance multiple times. Will these new products breathe new life into the stock?

This week's introduction of the NovaSeq Series of genomic sequencers caused the stock to jump on hopes the NovaSeq would restart the company's disappointing equipment sales. The NovaSeq promises to be the most powerful sequencer the company has ever launched.

In 2010, the company introduced the HiSeq line of products that enabled researchers to sequence an entire human genome for $1,000. The NovaSeq is expected to reduce that cost to $100 one day.

Recall that it took the Human Genome Project 13 years and $3 billion to do what these machines can now do in days. For example, the HiSeq X Ten machine can sequence 16 people's DNA in three days for $1,000 per genome and can sequence 18,000 human genomes a year.

Management said its NovaSeq 5000 would be priced at $850,000 and is expected to ship in mid-2017. The NovaSeq 6000 would carry a $985,000 price tag and start shipping to customers in March.

The NovaSeq line is a complete redesign of the company's sequencing products and is expected to generate three times the output of its current sequencers while being 20% more economical. Labs doing "deep genomics" are going to love these machines.

The NovaSeq is really the first step of something called "clinical genomics." The promise of clinical genomics (or clinical oncology) is to allow doctors to sequence a patient's particular type of cancer and design a custom treatment regiment in the office at an affordable price.

Some the company's largest customers, such as the Broad Institute of MIT and Harvard and Craig Venter's Human Longevity, Inc., have already placed orders. The Broad Institute is the largest producer of human genomic information in the world. Illumina said it has already sold 49 instruments, which is double what it can manufacture.

In addition to the new line of products, Illumina recently announced it would spin out GRAIL, a venture-backed start-up designed to develop a pan-cancer test to measure circulating nucleic acids (ctDNA) in blood. Illumina created GRAIL about a year ago, which has raised $40 million from Illumina and the rest from several venture funds.

GRAIL's goal is to enroll 10,000 participants and sequence their genetic information with the goal of commercializing its pan-cancer test within three years. Furthermore, the start-up also has the ambitious goal of screening hundreds of thousands of individuals which would make GRAIL a gigantic customer of Illumina.

Back in October, I was cautious on shares of Illumina because the company's numerous reductions to guidance. On Tuesday, the company announced preliminary fourth-quarter revenue of $619 million, slightly ahead of the previously announced guidance of $607 million-$612 million and adjusted earnings of $3.60-3.70 per share.

I have been largely positive on the company and its technology for a long time, but it has essentially run out of customers who can afford to throw down $10 million for a fully loaded HiSeq X Ten genomic sequencer and cough up $500,000 a year for consumable reagents.

For me to get more constructive on the stock, I would have to see Illumina post double-digit revenue growth. As early as 2014, the company was reporting revenue growth of 31% as the Chinese were buying machines like crazy. But in 2016, Illumina will report revenue growth of only 8% and earnings growth of 9.7%.

I am hopeful the NovaSeq series can rejuvenate the top line. If it does, 2016 will be the bottom and revenue growth should pick back up to double digits in 2017 and 2018. I remain cautiously optimistic on shares of Illumina.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Laudani had no positions in any stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Earnings

More from Healthcare

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Here's Why Eli Lilly Broke to the Upside

Bruce Kamich
Jan 11, 2021 1:00 PM EST

Let's review the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login